Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of Istaroxime for Acute Heart Failure in patients with low systolic blood pressure (SBP) and those who are diuretic resistant

Trial Profile

A phase II study of Istaroxime for Acute Heart Failure in patients with low systolic blood pressure (SBP) and those who are diuretic resistant

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istaroxime (Primary)
  • Indications Acute heart failure
  • Focus Therapeutic Use

Most Recent Events

  • 25 Oct 2021 According to a Windtree Therapeutics media release, the company will also include as secondary endpoints, assessments that could potentially become primary pivotal endpoints in the Phase 3 program and thus put the program in what the company believes will be a good Phase 3 ready and partnership position.
  • 25 Oct 2021 According to a Windtree Therapeutics media release, company plans to start the next acute heart failure study by mid-2022 and look to optimize istaroxime dosing by employing a longer infusion duration.
  • 20 May 2020 According to a Windtree Therapeutics media release, the company has received net proceeds which will be used for the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top